Delving into the Latest Updates on Le Centre Hospitalier Universitaire de Toulouse with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Immune System Diseases

Hemic and Lymphatic Diseases

Synthetic peptide

AAV based gene therapy

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Immune System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

AAV based gene therapy	1
Synthetic peptide	1
Monoclonal antibody	1

Top 5 Target	Count

NAGLU(Alpha-N-acetylglucosaminidase)	1
APLNR(Apelin receptor)	1
CD39(Ectonucleoside triphosphate diphosphohydrolase 1)	1

AbstractPurpose of ReviewThe present review will examine bone disease in mastocytosis, analyze the existing literature on its management, and propose a strategy for osteoporosis treatment in systemic mastocytosis. This strategy is based on both the available scientific evidence and the experience gained at our expert center (CEREMAST).Recent FindingsSystemic mastocytosis is a rare disorder, primarily affecting the bone and leading to osteoporosis, bone pain, and bone structural abnormalities. While traditionally described in indolent systemic mastocytosis, bone involvement is also observed in bone marrow mastocytosis. The true prevalence of systemic mastocytosis is likely underreported, highlighting the importance for clinicians to be familiar with the condition, particularly in cases of osteoporosis. Osteoporosis management typically involves bisphosphonates, with potential benefits from combining them with specific treatments like interferon in severe osteoporosis with vertebral fractures. The potential of new mast cell-targeting molecules to treat bone involvement needs to be demonstrated.SummaryThis review provides a guide for osteoporosis and bone pain management in systemic mastocytosis.

01 Jun 2025·The Knee

Quadriceps and hamstring muscles strength differences in adolescent and adult recreational athletes 6 months after autograft bone–patellar-tendon–bone anterior cruciate ligament reconstruction: A retrospective study

Article

Author: Bacchin, Valentina ; Zatti, Giovanni ; Albanese, Fabio ; Alessandro, Cristiano ; Piatti, Massimiliano ; Bigoni, Marco ; Sugimoto, Dai ; Crippa, Marco ; Accadbled, Franck ; Rigamonti, Luca ; Benedettini, Erik ; Turati, Marco

BACKGROUNDKnee muscle strength recovery after anterior cruciate ligament reconstruction (ACLR) is crucial for a safe return to sport (RTS) but it is poorly described in the adolescent population. Therefore, we compared the knee muscle strength at 6 months post-surgery in adults and adolescents. We hypothesized a greater muscular strength in adolescents 6 months after ACLR.METHODSThis was a retrospective analysis of 55 adolescents (13-18 years old) and 76 adults (19-39 years old) who underwent ACLR with autograft bone-patellar-tendon-bone (BPTB), subjected to isokinetic tests 6 months after surgery. The following outcomes were analyzed: (1) the maximum torque of hamstrings (H) and quadriceps (Q) during flexion and extension at 30°/s normalized by body weight; (2) hamstrings to quadriceps strength ratio (HQ ratio); (3) injured to uninjured leg muscle strength ratio (limb-symmetry index, LSI).RESULTSBoth adults and adolescents produced lower Q torque with the injured leg compared with uninjured, but similar H torque. In adolescents, the injured Q torque and the Q-LSI were higher compared with adults. In both populations, the Q-LSI was lower than the H-LSI and the HQ ratio in the injured leg was higher compared with uninjured. Adolescents showed a lower HQ ratio in injured legs.CONCLUSIONSAt 6 months after ACLR both adolescents and adults did not recover Q strength in the injured leg. However, adolescents showed larger Q strength compared with adults. The HQ ratio analysis showed that 6 months after surgery both groups are not ready for a safe RTS.

01 Jun 2025·Journal of Affective Disorders

Clinical features and comorbidities associated with migraine in bipolar disorder: Results from the FACE-BD cohort

Article

Author: Samalin, Ludovic ; Leboyer, Marion ; Schwan, Raymund ; Llorca, Pierre-Michel ; Etain, Bruno ; Aouizerate, Bruno ; Polosan, Mircea ; Bellivier, Frank ; Januel, Dominique ; Olié, Emilie ; Lefrere, Antoine ; Walter, Michel ; Chalayer, Ambre ; Dubertret, Caroline ; Belzeaux, Raoul ; Bogdan, Anamaria ; Godin, Ophelia ; Rey, Romain ; Moisset, Xavier ; Courtet, Philippe ; Roux, Paul ; Haffen, Emmanuel ; Yrondi, Antoine ; Pelletier, Agnes

INTRODUCTIONIndividuals with bipolar disorder (BD) frequently experience comorbid medical conditions, with migraine being among the most common. While research on migraine prevalence in BD is growing, the associated clinical features, comorbidities, and treatments remain underexplored and sometimes inconsistent. This study aimed to investigate the clinical features and comorbidities associated with migraine in a large cohort of adults with BD.METHODSWe assessed 4348 outpatients with BD attending FondaMental Advanced Centers of Expertise. Sociodemographic and clinical data were collected using a standardized procedure. Lifetime diagnoses for medical disorders, including migraine, were based on self-reports, clinician assessments, and medical history reviews. Multivariable logistic regression was used to assess associations between migraine and sociodemographic factors, clinical characteristics, comorbidities, and medications.RESULTSThe prevalence of comorbid migraine in BD was 20 %, with 29.1 % in BD type II and 19.9 % in BD type I. Multivariable analysis found that migraine was associated with younger age (OR = 0.98, CI 95 % 0.97-0.99), females (OR = 2.15, CI 95 % 1.56-2.95), sleep disturbances (OR = 1.06, CI 95 % 1.02-1.11), childhood trauma (OR = 1.01, CI 95 % 1.00-1.02), hypertension (OR = 1.88, CI 95 % 1.13-3.15), psoriasis (OR = 1.61, CI 95 % 1.01-2.56), asthma (OR = 1.65, CI 95 % 1.02-2.67) and lower use of second-generation antipsychotics (OR = 0.65, CI 95 % 0.48-0.87).CONCLUSIONMigraine is common in BD, especially in younger individuals, females, and those with sleep disturbances or a history of trauma, who also experience a higher clinical burden. These overlapping factors highlight the need for an integrated treatment approach, addressing mood stabilization, sleep management, and trauma support to reduce migraine burden in BD patients.

100 Deals associated with Le Centre Hospitalier Universitaire de Toulouse

Login to view more data

100 Translational Medicine associated with Le Centre Hospitalier Universitaire de Toulouse

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Apelin-13 ( APLNR )	Diabetes Mellitus, Type 2 More	Phase 1
WO2024175604 ( NAGLU )	Nutritional and Metabolic Diseases More	Discovery
WO2024115935 ( CD39 )	Lymphoproliferative Disorders More	Discovery